DOSE OPTIMIZATION OF CEFTRIAXONE-SULBACTAM COMBINATION IN ADULTS USING IN VITRO SYSTEMS, PK/PD MODELING AND STOCHASTIC SIMULATIONS APPROACHES
Keywords:
PKPD modeling, monte-carlo simulations, ceftriaxone, sulbactam, dose optimizationAbstract
Objective: To optimize the dosage regimen of fixed-dose combination (FDC) of ceftriaxone/sulbactam (2/1 w/w) using in vitro system, pharmacokinetic/pharmacodynamic (PK/PD) modeling and Monte-Carlo simulations (MCS).
Methods: One compartment in vitro system was used for identification of PK/PD driver that best correlates with therapeutic potential of FDC against ESBL positive E. coli infection. Using in vitro approach, the best exposure from dose escalation study was fractionated twice-a-day (BID) and thrice-a-day (TID) to determine a best dosage regimen of the FDC. In second approach i.e. in silico PK/PD modeling, dose response curve was constructed to estimate curve parameters (EC50, γ, and Emax), which were then used to develop PK/PD model for the FDC. In the third approach, MCS were employed to evaluate the impact of different dosage regimen against mild-to-severe infections. Lastly, the recommendation of dose adjustments for patients with renal impairment was also presented.
Results: Based on all three approaches, the best antibacterial effect was obtained from the exposure of 20 x MICcomb, which when fractioned to twice-daily dosing showed a maximum reduction in bacterial densities for severe infections. Dose reduction was recommended for patients with several renal impairments.
Conclusion: FDC dosage regimen of 1.5g BD or 3g OD was recommended for mild to moderate infections; whereas 3g BD was required for severely infected patients.
Keywords: PK/PD modeling, Monte-carlo simulations, Ceftriaxone, Sulbactam, Dose optimization
Downloads
References
Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing enterobacteriaceae in europe. Eur Surveillance 2008;13:1-7.
Dhillon RH, Clark J. ESBLs: a clear and present danger? Crit Care Res Pract 2012:1-11.
Papp-Wallace KM. Carbapenems: the past, present, and future. Antimicrob Agents Chemother 2011;55:4943-60.
Sahu M. Waging war against extended-spectrum Beta-lactamase and metallobetalactamase producing pathogens-novel adjuvant antimicrobial agent cse1034-an extended hope. J Clin Diagn Res 2014;8:20-3.
Hall MJ, Westmacott D, Wong-Kai-In P. Comparative in vitro activity and mode of action of ceftriaxone (Ro 13-9904), a new highly potent cephalosporin. J Antimicrob Chemother 1981;8:193-203.
Chaudhary M, Kumar S, Payasi A. A novel approach to combat acquired multiple resistance in Escherichia coli by using EDTA as efflux pump inhibitor. J Microb Biochem Technol 2012;4:126-30.
Xiao X. In vitro dynamic pharmacokinetic/ pharmaco-dynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis. BMC Vet Res 2015;11:33-40.
Jaruratanasirikul S. Pharmacodynamics modeling to optimize dosage regimens of sulbactam. Antimicrob Agents Chemother 2013;57:3441-4.
Nielsen EI, Cars O, Friberg LE. Pharmacokinetic/ pharmaco-dynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 2011;55: 4619-30.
Den Hollander JG, Mouton JW, Verbrugh HA. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. Antimicrob Agents Chemother 1998;42:744-8.
Clinical and Laboratory Standards Institute (CLSI). Peformance standards for Antimicrobial disk diffusion susceptibility tests: approved standard. 12th Ed. CLSI M02-A12, Wayne, PA; 2015.
Ogden A. Evaluation of pharmacokinetic/pharmacodynamic relationships of PD-0162819, a biotin carboxylase inhibitor representing a new class of antibacterial compounds, using in vitro infection models. Antimicrob Agents Chemother 2012;56:24-9.
Pichereau S. Simulated antibiotic exposures in an in vitro hollow-fiber infection model influence toxin gene expression and production in community-associated methicillin-resistant staphylococcus aureus strain MW2. Antimicrob Agents Chemother 2012;56:140-7.
Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 2011;65:1053-90.
Patel IH, Chen S. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother 1981;20:634-41.
Foulds G, Stankewich JP. Pharmacokinetics of sulbactam in humans. Antimicrob Agents Chemother 1983;23:692-9.
Sharma VD, Singla A, Chaudhary M, Taneja M. Population pharmacokinetics of fixed dose combination of ceftriaxone and sulbactam in healthy and infected subjects. AAPS PharmSciTech 2015. Doi:10.1208/s12249-015-0454-2. [Article in Press]
Attili VS, Chaudhary M. Pharmacokinetics, and pharmacodynamics of Elores in complicated urinary tract infections caused by extended-spectrum beta-lactamase strains. Int J Pharm Sci Res 2015;6:2569-78.
Sharma VD, Singla A, Chaudhary M, Taneja M. Dose optimization of ceftriaxone-sulbactam combination in pediatric using in vitro systems and stochastic simulation approaches. Int J Pharm Sci Res 2016;7:1503-12.
Sharma VD, Singla A, Chaudhary M, Taneja M. Cost-effectiveness of ceftriaxone-sulbactam in treatment of nosocomial infections using probabilistic sensitivity analysis. Eur J Pharm Med Res 2016;3:454-62.